SOLABIA
Acquired by
ASTORG
SOLABIA acquired by ASTORG
Target
SOLABIA
Acquirer
ASTORG
Context
The private equity firm Astorg wins the auction to acquire the Solabia Group from TA Associates. This secondary LBO values the French biotech specialist at over EUR1.1 billion. The management team, led by CEO Jean-Baptiste Dellon, reinvests alongside Astorg. This new partnership aims to accelerate Solabia's international growth, particularly in the United States, and to continue its buy-and-build strategy to broaden its portfolio of natural ingredients for the beauty and health sectors.
SOLABIA, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level LOGIN as high as the 10.2x average currently observed in the Industry & Manufacturing sector.
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Industry & Manufacturing market trends
Target
A leading French biotechnology company specializing in the production of natural active ingredients. Founded in 1972, Solabia serves the cosmetics, pharmaceutical, and nutrition industries. The group is renowned for its expertise in extraction, fermentation, and enzymatic catalysis. Under the leadership of Jean-Baptiste Dellon, it has expanded globally through acquisitions (e.g., in Israel, Brazil, and the US).
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with SOLABIA
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.